Current status of hepatitis delta
- PMID: 33895531
- DOI: 10.1016/j.coph.2021.03.008
Current status of hepatitis delta
Abstract
Hepatitis D virus (HDV) infection in patients chronically infected with hepatitis B virus (HBV) causes the most severe form of chronic viral hepatitis and continues to represent a major health problem. The latest data show that the global prevalence is much higher than previously considered. Therefore, screening with the detection of anti-HDV antibodies is mandatory for all chronic HBV patients. In spite of the severity of liver disease, the only recommended treatment today is pegylated interferon-alpha, which has limited efficacy. Novel host-targeting molecules are now under investigation. The current phase 2 clinical trials include pegylated interferon-lambda, bulevirtide, lonafarnib, and REP-2139. This review focuses on the current status of epidemiology, diagnosis, and treatment of HDV infection.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of interest statement M Papatheodoridi has no conflict of interest; G Papatheodoridis has served as advisor/lecturer for, has received research grants from, and has participated in clinical trials sponsored by Gilead Sciences; he has participated as principal investigator in clinical trials sponsored by Eiger BioPharmaceuticals.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
